1 In rats a single injection of the alkaloid monocrotaline (60 mg MCT kg 71 body weight, i.p.) caused right ventricular hypertrophy and heart failure. The aim of this study was to ®nd out whether, in these MCT-treated rats, the cardiac neuronal noradrenaline uptake (uptake 1 ) might undergo chamber-speci®c alterations. 71 protein). 6 We conclude that in MCT-treated rats with right ventricular hypertrophy and heart failure uptake 1 activity is chamber-speci®cally reduced possibly due to a decrease in carrier protein density.
Introduction
During the last two decades growing evidence has accumulated that one typical feature of chronic heart failure, in humans as well as in experimental animal models, is a decrease in cardiac b-adrenoceptor function (for recent review see Brodde & Michel, 1999 ) that might be due to increased circulating noradrenaline, increased cardiac release of noradrenaline and/or a decreased cardiac neuronal noradrenaline uptake (uptake 1 ) activity (for recent review see Esler et al., 1997) . In fact, elevated circulating catecholamines (Thomas & Marks, 1978; Cohn et al., 1984) , reduced myocardial catecholamine stores (Chidsey & Braunwald, 1966; Anderson et al., 1992) , decreased neuronal uptake 1 (Petch & Nayler, 1979 ) and a reduction in density of noradrenaline carrier sites (BoÈ hm et al., 1995) have been described in the failing human heart. However, in animal models of right-sided and of left-sided heart failure a chamber-speci®c decrease in right or left ventricular neuronal uptake 1 was observed (Liang et al., 1989; Himura et al., 1993; Yoshikawa et al., 1994) indicating that local rather than systemic eects might be responsible for these changes. In patients with primary pulmonary hypertension, who exhibit isolated right ventricular failure, catecholamine stores were depleted only in the failing right ventricle but not in the nonfailing left ventricle . Similarly, chamber-speci®c depletion of myocardial stores were found in rabbits (Yoshikawa et al., 1994) , dogs (Liang et al., 1989) and transgenic rats (BoÈ hm et al., 1998) .
Monocrotaline (MCT) is a pyrrolizidine alkaloid of the Crotalaria spectabilis. A single injection of MCT in the rat causes pulmonary hypertension and right ventricular hypertrophy; part of these animals develop cardiac failure (Kay et al., 1967 ; for recent review see Doggrell & Brown, 1998) . In the present study we have used this MCT-rat model of pulmonary hypertension to further study whether local rather than systemic in¯uences may aect the neuronal noradrenaline uptake in the heart. For this purpose we have assessed in right and left ventricles of MCT-treated rats [ 3 H]-noradrenaline accumulation in tissue slices (as a measure of neuronal noradrenaline uptake 1 activity). In addition we have used binding of [ 3 H]-nisoxetine that has been recently shown to label the noradrenaline carrier sites in rat placenta (Shearman & Meyer, 1998) and rat heart (BoÈ hm et al., 1998) in crude right and left ventricular membranes to determine the density of the uptake 1 carrier sites. 
Methods
Induction of acute right ventricular hypertrophy and heart failure in rats by monocrotaline (MCT)
Six-week-old male Wistar rats (obtained from Moellegard, SchoÈ newald, Germany), housed in groups of three per cage in a controlled environment (12 h light/dark cycle at 228C), were randomly divided into two experimental groups: one group received an intraperitoneal (i.p.) injection of monocrotaline (MCT, 60 mg kg 71 body weight), and the other group an equal volume of 0.9% saline (1 ml kg 71 body weight). MCT was dissolved in 1 N HCl, neutralized with 1 N NaOH, diluted with 0.9% saline and then injected at a concentration of 24 mg ml
71
. The dosage of 60 mg MCT kg 71 i.p. was determined in pilot experiments and was selected with regard to survival and induction of cardiopulmonary injury.
MCT-treated rats had free access to food (25 g dry food day 71 per animal), whereas control rats were given only the quantity of food consumed by the MCT-treated rats the previous day (reduced to a minimum of 12.5 g dry food day 71 per animal). This diet was necessary because of toxic eects of MCT that elicit generalized illness and lack of appetite, mainly due to metabolic eects on the liver (Duecker et al., 1992) .
Four to 6 weeks after MCT-injection all MCT-treated animals had developed hypertrophied right ventricles. About 40 ± 50% of these animals showed signs of illness such as dyspnoea, cessation of eating, and loss of body weight. Within this time range the animals were anaesthetized with ether, killed by cervical dislocation and the hearts were rapidly excised. Meantime of sacri®ce of the rats was 5.2 weeks (4 ± 6 weeks). Right ventricular failure was con®rmed by the presence of ascites, pericardial or pleural eusions. An equal number of control animals were killed at the same time. The hearts were divided into right ventricle (RV) and left ventricle including intraventricular septum (LV) and the ratio of the weight of each ventricle to the body weight was calculated as an index for ventricular hypertrophy. Because MCT-treated rats had signi®cantly lost body weight (Table 1) we calculated in addition the ratio of LV/RV-weight as a body weight independent indicator of right ventricular hypertrophy. Subsequently right and left ventricular tissue were either directly used for measuring uptake 1 activity or quickly frozen in liquid nitrogen and stored at 7808C until use for crude membrane preparations. The remaining MCTtreated rats not developing signs of cardiac failure were killed 6 weeks after the MCT-injection and were used in another study (Seyfarth et al. , submitted for publication).
All animal experiments were performed according to the German laws for animal welfare approved by the local committee for animal studies. ]-noradrenaline uptake 1 activity was assessed as described by Liang et al. (1989) with minor modi®cations. Right and left ventricular tissue taken from saline-and MCT-treated rats was chopped in modi®ed Krebs-Henseleit solution (mM: NaCl 118, KCl 4.7, CaCl 2 2.5, MgCl 2 0.54, NaHCO 3 25, NaH 2 PO 4 1, glucose 11, EDTA 0.094, ascorbic acid 1.14, nialamide 0.067) into 2506250 mm slices with a McIllwain tissue chopper (Bachhofer, Reutlingen, Germany). The slices were resuspended in fresh Krebs-Henseleit solution, and noradrenaline uptake 1 activity was measured in duplicates by incubating 10 mg ventricular slices at 378C for 15 min in oxygenated Krebs-Henseleit solution containing 1.56, 3.125, 6.25, 12.5 and 25 nM D,L-[7-3 H(N)]-noradrenaline hydrochloride (13.5 Ci mmol
) in a ®nal volume of 500 ml. Nonspeci®c accumulation of radioactivity was determined by parallel incubation at 48C. The incubation was terminated by rapid ®ltration of the entire reaction mixture through Whatman GF/C ®lters that had been presoaked for 15 min in ice-cold Krebs-Henseleit solution containing 0.05% polyethylenimine. Each ®lter was washed three times with 2 ml of ice-cold Krebs-Henseleit solution and the ®lters were transferred into scintillation vials containing 3% trichloracetic acid (TCA), followed by an incubation at 48C overnight. The [ 3 H]-radioactivity was counted after adding 4 ml scintillation cocktail (Lumasafe TM Plus, Lumec; Groningen, Netherlands) by liquid scintillation spectrometry (Packard TRI-Carb 2250CA) at an eciency of 61%. Speci®c uptake was de®ned as total uptake (378C) minus unspeci®c uptake (48C). Six separate experiments were performed for control group and 12 for MCT-treated group.
Kinetic parameters of uptake 1
To characterize the transport kinetics of noradrenaline in right and left ventricles of saline-and MCT-treated rats tissue slices were incubated as described above. For determination of the kinetic parameters, unlabelled (7)-noradrenaline was mixed in the incubation medium with [ 3 H]-noradrenaline to give a ®nal noradrenaline concentration of 1.56 to 200 nM. Speci®c uptake was de®ned as total uptake (378C) minus unspeci®c uptake (48C). Three separate experiments were performed for control group and six for MCT-treated group.
Drug competition experiments
Competition studies with desipramine, nisoxetine, cocaine and GBR 12909 were conducted as described above by incubating tissue slices taken from left ventricles of saline-treated rats with a ®xed concentration of [ 3 H]-noradrenaline (25 nM) in the presence of eight concentrations of each competitive drug and speci®c uptake was determined as described earlier. Five separate experiments were performed for each drug.
To further clarify which uptake system (uptake 1 or uptake 2 ) was active under the experimental conditions described above, tissue slices taken from right and left ventricles of saline-and MCT-treated rats were incubated with a ®xed concentration of [ 3 H]-noradrenaline (25 nM) in the presence or absence of 40 mM of the uptake 2 -inhibitor corticosterone or 1 mM of the uptake 1 -inhibitor nisoxetine. Nonspeci®c accumulation of radioactivity was determined by parallel incubation at 48C. Speci®c uptake was de®ned as British Journal of Pharmacology vol 131 (7) Cardiac uptake 1 in MCT-treated rats K. Leineweber et altotal uptake (378C) minus unspeci®c uptake (48C). Three separate experiments were performed for each drug. 
H]-nisoxetine saturation analysis and drug competition experiments
The preparation of crude membranes isolated from right and left ventricles of saline-and MCT-treated rats for [ 3 H]-nisoxetine binding studies was performed as described by Shearman & Meyer (1998) , with minor modi®cations. 100 ± 150 mg of frozen right and left ventricle were thawed on ice in 5 ml incubation buer (mM: Na 2 HPO 4 10, NaCl 120, KCl 5, pH 7.4) containing 0.25 M sucrose. The tissue was minced with scissors and gradually homogenized with an UltraTurrax (Ultra-Turrax T25, Jahne & Kunkel IKA 1 Labortechnik, Germany) at maximal setting (24 000 r.p.m.) for 10 s and twice at 17 500 r.p.m. for 20 s with 1 min intervals at 48C. The homogenate was brought up to 20 ml with incubation buer (+0.25 M sucrose) and centrifuged at 12006g for 10 min at 08C. The supernatant was ®ltered through four layers of cheesecloth and centrifuged at 20 0006g for 20 min at 48C. The resulting pellet was resuspended in 20 ml incubation buer (+0.25 M sucrose) and recentrifuged at 20 0006g for 20 min at 48C. The ®nal crude membrane pellets were resuspended in ice-cold incubation buer (without sucrose) yielding a protein concentration of 250 mg ml 71 . Protein content was determined according to Bradford (1976) using bovine g-globulin as a standard.
[ 3 H]-nisoxetine saturation analysis was performed by incubating 100 mg protein per assay with six concentrations of [ 3 H]-nisoxetine ranging from 0.3125 to 10 nM in a ®nal assay volume of 500 ml for 3 h at 48C. Incubation was terminated by adding 5 ml of ice-cold incubation buer to the reaction mixture followed by rapid ®ltration through Whatman GF/C ®lters. Each ®lter was washed two times with 5 ml incubation buer. The ®lters were transferred to scintillation vials and dried overnight. Thereafter 4 ml scintillation cocktail (Lumasafe TM Plus, Lumac; Groningen, Netherlands) was added, and the radioactivity was determined in a Packard TRI-Carb 2250CA scintillation counter at an eciency of 61%.`Unspeci®c' binding of [ ]-nisoxetine and with eight dierent concentrations of the competing agents for 3 h at 48C, and speci®c binding was determined as described above. The competition curves were analysed using the iterative curve ®tting programme Prism (GraphPad Software, San Diego, CA, U.S.A.) from which the individual IC 50 -values (concentration of the competing agent to inhibit speci®c binding by 50%) were obtained. Six separate experiments were performed for each drug.
Data analysis
The experimental data given in text, ®gures and tables are expressed as the means+s.e.mean of n experiments. The equilibrium dissociation constants (K D ) and the maximal number of binding sites (B max ) for [ 
Results
Characterization of MCT-treated rats with experimental induced right heart failure Alterations in body weight and heart weight of MCT-treated rats are given in Table 1 . Between 4 and 6 weeks after MCTinjection the body weight was markedly reduced vs salinetreated rats. The MCT-treated rats exhibited a signi®cant enlargement of the right ventricle (about 2 fold) and the ratio RV/body weight was signi®cantly increased; moreover the LV/RV-ratio, as an indicator of right ventricular hypertrophy independent of body weight, was signi®cantly reduced in MCT-treated rats vs controls. On the other hand, the LV/ body weight ratio was only slightly (but signi®cantly) increased in MCT-treated rats vs controls (Table 1 ).
Characterization of [
3 H]-noradrenaline uptake 1 in ventricular slices of the rat heart . Nonspeci®c noradrenaline-accumulation at 48C was less than 5% (data not shown).
Since uptake 1 is governed by saturation kinetics of the Michaelis-Menten type (for review see Graefe & BoÈ nisch, 1988) , we next assessed the half-saturating concentration (K M ) and the maximal initial transport rate (V max ) of [ Table 4 ), while the speci®c dopamine-uptake inhibitor GBR 12909 (Giros et al., 1992) was only a weak inhibitor (IC 50 -value 46 mM; Figure 4 , Table 4 ). Finally, cocaine inhibited [ noradrenaline uptake 1 with an IC 50 -value (about 4 mM) that is in its range for its anity to uptake 1 (Jayanthi et al., 1993; Paczkowski et al., 1999 50 -value (about 5 mM) that is well in its range of anity to the noradrenaline uptake 1 carrier site in several tissues (Tejani-Butt, 1992; Jayanthi et al., 1993) .
Changes in noradrenaline uptake 1 characteristics in MCT-treated rats [ 3 H]-noradrenaline uptake 1 activity Compared to salinetreated rats in right ventricular slices of MCT-treated rats Table 3 ). In contrast, in membranes from left ventricles of MCT-treated rats the maximal number of [ 3 H]-nisoxetine binding sites was nearly identical with that determined in control rats ( Figure 3 , Table 3 ).
Discussion
It is well known that in several organs, including the heart, the major mechanism responsible for removal of neuronally released noradrenaline is the noradrenaline uptake transporter located on sympathetic nerve terminals (von Euler, 1972 ; , 1991) . In the present study we have assessed ]-nisoxetine binding to membranes were inhibited by uptakeinhibitors with an order of potency desipramine4nisoxeti-ne44cocaine5GBR 12909, that is a typical one for noradrenaline uptake 1 (Tejani-Butt, 1992; Jayanthi et al., 1993; Paczkowski et al., 1999) ; in addition, IC 50 -values were Values are means+s.e.mean; n, number of experiments.
British Journal of Pharmacology vol 131 (7) very well comparable in the two settings. Moreover, corticosterone, an inhibitor of uptake 2 , used in a concentration of 40 mM, did not at all aect [ 3 H]-noradrenaline accumulation in right and left ventricular slices (of control as well as MCTtreated rats) although in this concentration it has been shown to completely suppress uptake 2 activity (Starke et al., 1974) . These data, therefore strongly support the view that with our approach we have assessed uptake 1 activity and density of carrier sites in right and left ventricles of the rat heart.
In the present study we have used the MCT-rat model of pulmonary hypertension to study the hypothesis (see Introduction) that cardiac neuronal noradrenaline uptake 1 is regulated primarily by local mechanisms. A single i.p. injection of 60 mg kg 71 MCT resulted within 4 ± 6 weeks in rapid development of right ventricular hypertrophy; part of these animals developed heart failure as indicated by signs of ascites and pleural eusions. On the other hand, left ventricular weight was nearly not altered in MCT-treated rats. In this study we did not measure right ventricular systolic pressure; however, we recently had determined right ventricular pressure in another group of MCT-treated rats with signs of heart failure and had found, that in these rats right ventricular systolic pressure (46.4+5.3 mmHg, n=7) was signi®cantly (P50.01) higher than in control rats (13.1+0.5 mmHg, n=13), whereas mean arterial blood pressure was not dierent in the two groups (86.3+5.5 vs 96.2+2.6 mmHg; Seyfarth et al. (submitted) .
These data demonstrate that MCT-treatment caused primarily chamber-speci®c right ventricular hypertrophy (and right ventricular failure; for review see Doggrell & Brown, 1998) , although in the present study a slight but signi®cant increase in LV/body weight ratio was also observed (see Table 1 ). However, this increase might not indicate LV hypertrophy but is mainly due to the fact that in MCT-treated rats body weight was signi®cantly lower than in control rats while left ventricular weight did not dier between the two groups.
In these MCT-treated rats right ventricular [ 3 H]-noradrenaline accumulation (as a measure of uptake 1 activity) was signi®cantly reduced by about 42% (Figure 1A,B) . This might be due to a decrease in the density of carrier protein, since the [ 3 H]-nisoxetine binding sites were reduced in right ventricles of MCT-treated rats by about the same amount (41%; Table 3 ).
Correspondingly the maximal initial transport rate (V max ) of noradrenaline was markedly reduced in right ventricles of MCT-treated rats as was the noradrenaline concentration that is necessary to half-saturates uptake 1 (K M ; see Table 2 ). Liang et al. (1989) showed similar changes in noradrenaline uptake 1 activity and carrier density in right ventricles of dogs with right heart failure produced by tricuspid avulsion and progressive pulmonary artery constriction. Himura et al. (1993) observed under the same conditions a chamber-speci®c loss of noradrenergic nerve terminals, as evidenced by a reduction in catecholaminergic histo¯uorescence-and tyrosine hydroxylase-immunoreactive pro®les. The same group recently showed that chronic ACE inhibition attenuated these reductions of the noradrenaline clearance system possibly due to a protective eect of ACE inhibitors on the sympathetic nerve terminal integrity and function (Kawai et al., 1999) .
On the contrary, no such changes could be observed in the left ventricle of MCT-treated rats. In comparison to left ventricles of saline-treated rats the noradrenaline uptake 1 activity was not decreased, but rather elevated in MCTtreated rats. In addition, the uptake 1 carrier protein density was not signi®cantly altered compared to saline-treated rats. Moreover, an increase of the maximal transport rate (about 2 fold) could be measured in left ventricles of MCT-treated rats accompanied by an increase of K M to about the same extent. That leads to the assumption that the noradrenaline uptake 1 activity might be upregulated in these ventricles by increasing the transport cycle of noradrenaline per carrier and not by altering the carrier density possibly to compensate systemspeci®cally the reduced noradrenaline clearance in right ventricles of hypertrophied hearts.
In conclusion, in rats MCT-treatment resulted in right heart hypertrophy and right heart failure with signi®cantly reduced uptake 1 activity and noradrenaline transporter density in the failing right ventricle. On the other hand, in left ventricle of MCT-treated rats noradrenaline transporter density was unchanged and transporter capacity slightly upregulated.
Thus, the present results clearly demonstrate that also in MCT-treated rats with right ventricular hypertrophy and heart failure cardiac noradrenaline uptake 1 is regulated by local rather than systemic in¯uences. This work was supported by a grant of the Deutsche Forschungsgemeinschaft (DFG Br 526/6-1).
